Overview

Efficacy of Clarithromycin and Flouroquinolones Based Regimens in H.Pylori Eradication in Covid-19 Era

Status:
Recruiting

Trial end date:
2021-11-21

Target enrollment:
0

Participant gender:
All

Summary

Era of COVID-19 and the related panic lead to widely spread antibiotics misuse especially for azithromycin. Cross sensitivity between azithromycin and clarithromycin can impact success rates of H. pylori treatment regimens.(1) Here we aim to explore this point in Egyptian patients. Sample size Supposing the cure rate of clarithromycin-based regimen to levofloxacin based regimen is 69% versus 84.5% respectively. Using Medcalc, the minimal required sample size is 116 patients for each arm (type 1 error= 5%, type II error=20%). Each arm increased by 10% to compensate for drop-out. The sample size will be 135 for each arm. Study Arms: - Arm 1: The first group will receive (amoxicillin 1g/12 hrs, Clarithromycin 500 mg/12hrs, esomeprazole 40mg/12hrs) - Arm 2: The second group will receive (esomeprazole 40 mg/12hrs, levofloxacin 500 mg/24 hrs, and amoxicillin 1gm/12 hrs). - To confirm patient compliance, we will ask patients to bring their remaining medication and counted the rest of their pills. Patients with a compliance of <80% will be excluded from the study per protocol (PP) analysis.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Alexandria University

Treatments:

Amoxicillin
Clarithromycin
Levofloxacin

Criteria

Inclusion Criteria:

- • Patients aged 18-64 years old with newly diagnosed positive H. pylori antigen in
stools, urea breath test or H. pylori detected on endoscopy.

Exclusion Criteria:

- • Women who were pregnant or lactating, patients previously treated with H. pylori
eradication therapy, patients who previously underwent gastric surgery, patients with
malignant neoplasms, and patients with other severe concomitant diseases like renal,
hepatic impairement, heart failure NYHA class II or more, hypoalbuminemia will be
excluded.

- Known allergy to antibiotics.